Agomab Therapeutics to acquire Origo Biopharma
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Belgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Paris-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
German CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.
Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, organised by EuropaBio and conference partners.
Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of its antibody duo AZD7442.
BionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.
A comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
The EIF has invested 25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest 307m in the company’s producion site near Dublin.